At present there is no standard second - line therapy for advanced bladder cancer. (sciencedaily.com)
To increase public awareness about bladder cancer; to advance bladder cancer research; and to provide educational and support services for the bladder cancer community. (diseaseinfosearch.org)
Based primarily on clinical trials led by Arjun V. Balar, MD, assistant professor of medicine and director of the Genitourinary Medical Oncology Program, the FDA approved atezolizumab (Tecentriq ®) and pembrolizumab (Keytruda ®) as first - line treatments for these particularly frail patients with advanced bladder cancer in early 2017. (nyulangone.org)